We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Haemonetics Gains on Strong Plasma, Wider Global Footprint
Read MoreHide Full Article
On Jul 16, we issued an updated research report on Haemonetics Corporation (HAE - Free Report) . The company has been benefiting from a steady momentum in new business generation and geographical expansion. The stock carries a Zacks Rank #2 (Buy).
Shares of this leading provider of hematology products and solutions have outperformed its industry over the past year. The stock has skyrocketed 134.9% compared with the industry’s 13% rally.
Haemonetics has successfully demonstrated a consistent trend in new business formation along with widening of its global footprint, which has further helped the company deliver strong results over the last few quarters. Moreover, the gross and the operating margin growth buoys optimism among investors on the stock.
Additionally, we are upbeat about Haemonetics’ flourish in the Plasma franchise. Solid end-market demand for plasma-derived biopharmaceuticals keeps driving growth. Haemonetics is also confident about maintaining progress in the commercial Plasma collection business.
Moreover, the fiscal 2019 guidance looks promising. In addition, the company’s strong cash position boosts investors’ confidence.
On the flip side, Haemonetics operates in a fiercely competitive environment with respect to manual and automated systems including the likes of MAK Systems.
Moreover, the company has been witnessing sluggish revenue growth at the Blood Center franchise, significantly affecting its results over the past few quarters. Also, management doesn’t expect a quick recovery in the Blood Center’s outcome, making matters even worse .
Other Key Picks
Some other top-ranked stocks in the broader medical space are Genomic Health , Align Technology, Inc. (ALGN - Free Report) and Stryker Corporation (SYK - Free Report) .
Align Technology has a projected long-term earnings growth rate of 28.2% and a Zacks Rank of 1.
Stryker has an estimated long-term earnings growth rate of 9.7% and a Zacks Rank of 2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Haemonetics Gains on Strong Plasma, Wider Global Footprint
On Jul 16, we issued an updated research report on Haemonetics Corporation (HAE - Free Report) . The company has been benefiting from a steady momentum in new business generation and geographical expansion. The stock carries a Zacks Rank #2 (Buy).
Shares of this leading provider of hematology products and solutions have outperformed its industry over the past year. The stock has skyrocketed 134.9% compared with the industry’s 13% rally.
Haemonetics has successfully demonstrated a consistent trend in new business formation along with widening of its global footprint, which has further helped the company deliver strong results over the last few quarters. Moreover, the gross and the operating margin growth buoys optimism among investors on the stock.
Haemonetics Corporation Price
Haemonetics Corporation Price | Haemonetics Corporation Quote
Additionally, we are upbeat about Haemonetics’ flourish in the Plasma franchise. Solid end-market demand for plasma-derived biopharmaceuticals keeps driving growth. Haemonetics is also confident about maintaining progress in the commercial Plasma collection business.
Moreover, the fiscal 2019 guidance looks promising. In addition, the company’s strong cash position boosts investors’ confidence.
On the flip side, Haemonetics operates in a fiercely competitive environment with respect to manual and automated systems including the likes of MAK Systems.
Moreover, the company has been witnessing sluggish revenue growth at the Blood Center franchise, significantly affecting its results over the past few quarters. Also, management doesn’t expect a quick recovery in the Blood Center’s outcome, making matters even worse .
Other Key Picks
Some other top-ranked stocks in the broader medical space are Genomic Health , Align Technology, Inc. (ALGN - Free Report) and Stryker Corporation (SYK - Free Report) .
Genomic Health has an expected earnings growth rate of 187.5% for the quarter to be reported. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology has a projected long-term earnings growth rate of 28.2% and a Zacks Rank of 1.
Stryker has an estimated long-term earnings growth rate of 9.7% and a Zacks Rank of 2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>